Humacyte, Inc. (HUMA) stock

HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30

$0.60+0.00 (+0.63%)

Close on Nov 12, 2026Market cap $165.40MP/E –Yield –

Humacyte r&d expenses

Research and development expenses are spending on new products and technology.

Humacyte's R&D Expenses for the twelve months ending Sep 30, 2026 was $66.32M, down 12.0% year over year. For fiscal 2025 it was $69.30M, down 21.8% from the year before. The highest annual figure on record is $88.60M in fiscal 2024.

Annual r&d expenses

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$69.30M	-21.8%
FY2024	Dec 31, 2024	$88.60M	+15.7%
FY2023	Dec 31, 2023	$76.55M	+21.0%
FY2022	Dec 31, 2022	$63.26M	+3.1%
FY2021	Dec 31, 2021	$61.34M	+13.4%
FY2020	Dec 31, 2020	$54.08M	–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$14.10M	-18.3%
Q2 FY2026	Jun 30, 2026	$18.14M	-17.5%
Q1 FY2026	Mar 31, 2026	$19.46M	+26.2%
Q4 FY2025	Dec 31, 2025	$14.61M	-29.3%
Q3 FY2025	Sep 30, 2025	$17.27M	-24.7%
Q2 FY2025	Jun 30, 2025	$22.01M	-7.4%
Q1 FY2025	Mar 31, 2025	$15.42M	-27.5%
Q4 FY2024	Dec 31, 2024	$20.66M	+2.4%
Q3 FY2024	Sep 30, 2024	$22.93M	+23.6%
Q2 FY2024	Jun 30, 2024	$23.75M	+15.6%
Q1 FY2024	Mar 31, 2024	$21.26M	+23.1%
Q4 FY2023	Dec 31, 2023	$20.18M	+34.9%
Q3 FY2023	Sep 30, 2023	$18.55M	+7.0%
Q2 FY2023	Jun 30, 2023	$20.54M	+40.2%
Q1 FY2023	Mar 31, 2023	$17.28M	+5.9%
Q4 FY2022	Dec 31, 2022	$14.96M	-8.0%
Q3 FY2022	Sep 30, 2022	$17.34M	+12.7%
Q2 FY2022	Jun 30, 2022	$14.65M	+0.6%
Q1 FY2022	Mar 31, 2022	$16.31M	+7.8%
Q4 FY2021	Dec 31, 2021	$16.25M	+23.1%
Q3 FY2021	Sep 30, 2021	$15.39M	+4.7%
Q2 FY2021	Jun 30, 2021	$14.57M	–
Q1 FY2021	Mar 31, 2021	$15.14M	–
Q4 FY2020	Dec 31, 2020	$13.20M	–
Q3 FY2020	Sep 30, 2020	$14.69M	–